The results and conclusions of the work conducted by the Lymphoma Research Experts ecosystem are published in leading medical journals.
Lysa
2024_Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort
Eur J Cancer 2024;208:114210
Learn more
Lysa
2024_Efficacy and Tolerance of Brexucabtagene Autoleucel in Adults with R/R B-ALL : A GRAALL study from the DESCAR-T registry
Blood Advances 2024;:bloodadvances.2024013962
Learn more
Lysa
2024_Outcome of large B-cell lymphoma patients treated with tafasitamab plus lenalidomide either before or after CAR-T-cells
Blood Adv 2024;:bloodadvances.2024013726
Learn more
Lysa
2024_Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration
Leukemia 2024;:
Learn more
Lysa
2024_CAR T-cells in very elderly (≥80 years) lymphoma patients: a DESCAR-T analysis
Leuk Lymphoma 2024;:1-4
Learn more
Lysa
2024_Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
J Hematol Oncol 2024;17:61
Learn more
Lysa
2024_IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma
Haematologica 2024;109:2564-2573
Learn more
Lysa
2024_Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma
Blood 2024;144:262-271
Learn more
Lysa
2024_Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma
Blood 2024;144:334-338
Learn more
Lysa
2024_Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital
Hematol Oncol 2024;42:e3297
Learn more
Lysa
2024_High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia
Blood 2024;143:2804-2807
Learn more
Lysa
2024_Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry
Haematologica 2024;:
Learn more
Lysa
2024_Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group
Haematologica 2024;109:1857-1865
Learn more
Lysa
2024_Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study
Lancet Haematol 2024;11:e406-e414
Learn more
Lysa
2024_French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry
Br J Haematol 2024;:
Learn more
Lysa
2024_Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial
J Clin Oncol 2024;42:1612-1618
Learn more
Lysa
2024_Lymphoma in Patients with Inflammatory Bowel Disease: A Multicentre Collaborative Study Between GETAID and LYSA
J Crohns Colitis 2024;18:533-539
Learn more
Lysa
2024_Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study)
Blood Adv 2024;8:1573-1585
Learn more
Lysa
2024_The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients
Blood 2024;143:983-995
Learn more
Lysa
2024_Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study
J Clin Oncol 2024;42:769-773
Learn more
Lysa
2024_Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial
JCO 2024;42:538-549
Learn more
Lysa
2024_Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial
2024;65:313-319
Learn more
Lysa
2024_Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy
Blood 2024;143:422-428
Learn more
Lysa
2024_Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort
Blood Advances 2024;8:296-308
Learn more